NASDAQ:EDIT

Editas Medicine Competitors

$39.46
-1.30 (-3.19 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.76
Now: $39.46
$40.35
50-Day Range
$39.71
MA: $45.00
$56.49
52-Week Range
$21.41
Now: $39.46
$99.95
Volume1.01 million shs
Average Volume2.52 million shs
Market Capitalization$2.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.1

Competitors

Editas Medicine (NASDAQ:EDIT) Vs. NBIX, CRSP, XLRN, FATE, TWST, and DNLI

Should you be buying EDIT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Editas Medicine, including Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Acceleron Pharma (XLRN), Fate Therapeutics (FATE), Twist Bioscience (TWST), and Denali Therapeutics (DNLI).

Neurocrine Biosciences (NASDAQ:NBIX) and Editas Medicine (NASDAQ:EDIT) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neurocrine Biosciences and Editas Medicine, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences081202.60
Editas Medicine34402.09

Neurocrine Biosciences currently has a consensus price target of $129.2222, suggesting a potential upside of 38.43%. Editas Medicine has a consensus price target of $50.10, suggesting a potential upside of 26.96%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Editas Medicine.

Insider and Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 87.5% of Editas Medicine shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 0.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Neurocrine Biosciences and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Editas Medicine-99.62%-26.74%-16.38%

Volatility and Risk

Neurocrine Biosciences has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Earnings and Valuation

This table compares Neurocrine Biosciences and Editas Medicine's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.13$37.01 million$0.39239.36
Editas Medicine$20.53 million129.48$-133,750,000.00($2.68)-14.72

Neurocrine Biosciences has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Neurocrine Biosciences beats Editas Medicine on 12 of the 14 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Editas Medicine and CRISPR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34402.09
CRISPR Therapeutics241202.56

Editas Medicine presently has a consensus price target of $50.10, indicating a potential upside of 26.96%. CRISPR Therapeutics has a consensus price target of $158.80, indicating a potential upside of 37.20%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Editas Medicine.

Insider & Institutional Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Comparatively, 17.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Editas Medicine and CRISPR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
CRISPR Therapeutics-273.10%-20.72%-18.35%

Risk & Volatility

Editas Medicine has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500.

Earnings & Valuation

This table compares Editas Medicine and CRISPR Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million129.48$-133,750,000.00($2.68)-14.72
CRISPR Therapeutics$289.59 million30.15$66.86 million$1.1798.92

CRISPR Therapeutics has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

CRISPR Therapeutics beats Editas Medicine on 9 of the 14 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Acceleron Pharma (NASDAQ:XLRN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Editas Medicine and Acceleron Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34402.09
Acceleron Pharma031012.86

Editas Medicine presently has a consensus price target of $50.10, indicating a potential upside of 26.96%. Acceleron Pharma has a consensus price target of $148.2143, indicating a potential upside of 16.84%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than Acceleron Pharma.

Insider & Institutional Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 79.8% of Acceleron Pharma shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Comparatively, 2.5% of Acceleron Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Editas Medicine and Acceleron Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Acceleron Pharma-157.84%-31.62%-28.11%

Risk & Volatility

Editas Medicine has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Earnings & Valuation

This table compares Editas Medicine and Acceleron Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million129.48$-133,750,000.00($2.68)-14.72
Acceleron Pharma$73.99 million103.81$-124,860,000.00($2.38)-53.30

Acceleron Pharma has higher revenue and earnings than Editas Medicine. Acceleron Pharma is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Summary

Editas Medicine beats Acceleron Pharma on 8 of the 15 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Editas Medicine and Fate Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million129.48$-133,750,000.00($2.68)-14.72
Fate Therapeutics$10.68 million684.84$-98,150,000.00($1.44)-54.16

Fate Therapeutics has lower revenue, but higher earnings than Editas Medicine. Fate Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Editas Medicine has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Editas Medicine and Fate Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34402.09
Fate Therapeutics04902.69

Editas Medicine presently has a consensus price target of $50.10, indicating a potential upside of 26.96%. Fate Therapeutics has a consensus price target of $108.3125, indicating a potential upside of 38.88%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Editas Medicine.

Profitability

This table compares Editas Medicine and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Fate Therapeutics-810.13%-35.51%-25.40%

Insider & Institutional Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Comparatively, 21.4% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Fate Therapeutics beats Editas Medicine on 8 of the 14 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Insider and Institutional Ownership

87.5% of Editas Medicine shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 0.9% of Editas Medicine shares are owned by insiders. Comparatively, 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Editas Medicine and Twist Bioscience, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34402.09
Twist Bioscience11202.25

Editas Medicine presently has a consensus price target of $50.10, indicating a potential upside of 26.96%. Twist Bioscience has a consensus price target of $133.3333, indicating a potential upside of 0.83%. Given Editas Medicine's higher probable upside, equities research analysts plainly believe Editas Medicine is more favorable than Twist Bioscience.

Profitability

This table compares Editas Medicine and Twist Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Twist Bioscience-155.31%-44.62%-35.49%

Earnings and Valuation

This table compares Editas Medicine and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million129.48$-133,750,000.00($2.68)-14.72
Twist Bioscience$90.10 million71.39$-139,930,000.00($3.00)-44.08

Editas Medicine has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

Editas Medicine beats Twist Bioscience on 10 of the 14 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and Editas Medicine (NASDAQ:EDIT) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider and Institutional Ownership

68.2% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 19.3% of Denali Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Denali Therapeutics and Editas Medicine, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Denali Therapeutics01702.88
Editas Medicine34402.09

Denali Therapeutics currently has a consensus target price of $75.8571, indicating a potential upside of 45.15%. Editas Medicine has a consensus target price of $50.10, indicating a potential upside of 26.96%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Editas Medicine.

Profitability

This table compares Denali Therapeutics and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Denali Therapeutics-968.59%-39.19%-30.71%
Editas Medicine-99.62%-26.74%-16.38%

Earnings & Valuation

This table compares Denali Therapeutics and Editas Medicine's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$26.68 million236.98$-197,610,000.00($2.07)-25.25
Editas Medicine$20.53 million129.48$-133,750,000.00($2.68)-14.72

Editas Medicine has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Denali Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.

Ad Legacy Research
Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video)
"Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project… What happens next will shock you…"

Editas Medicine Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$115.74-4.0%$8.73 billion$289.59 million-35.50Gap Down
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$126.85-1.9%$7.68 billion$73.99 million-48.98Gap Down
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$77.99-1.3%$7.31 billion$10.68 million-42.39Analyst Revision
Twist Bioscience logo
TWST
Twist Bioscience
1.2$132.23-0.1%$6.43 billion$90.10 million-35.26Analyst Upgrade
Insider Selling
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$52.26-1.4%$6.32 billion$26.68 million-23.65Insider Selling
News Coverage
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$40.42-4.0%$5.63 billion$85.07 million-42.55Insider Selling
News Coverage
Gap Down
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$109.07-1.1%$5.58 billionN/A-47.01
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$43.13-3.9%$5.52 billion$8.09 million-18.28Analyst Upgrade
Gap Down
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.00-0.2%$4.64 billion$503.70 million32.96
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.82-2.5%$4.62 billionN/A-15.41News Coverage
Gap Down
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.19-3.7%$4.44 billionN/A-15.72Unusual Options Activity
News Coverage
Gap Down
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$70.23-6.5%$4.39 billion$20,000.00-5.00News Coverage
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$68.95-3.5%$3.38 billionN/A-39.63Gap Down
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$70.33-0.1%$3.14 billion$125.57 million-41.13
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$42.67-5.5%$3.13 billion$50.04 million0.00Insider Selling
Gap Down
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$33.63-5.1%$3.04 billionN/A0.00Gap Down
Vericel logo
VCEL
Vericel
1.3$57.77-3.5%$2.66 billion$117.85 million-5,777,000.00News Coverage
Gap Down
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.51-3.1%$2.11 billion$31.43 million-5.14News Coverage
Gap Down
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.88-1.0%$1.94 billionN/A-11.16
bluebird bio logo
BLUE
bluebird bio
1.8$28.16-2.5%$1.89 billion$44.67 million-2.56
NantKwest logo
NK
NantKwest
1.1$16.87-10.8%$1.84 billion$40,000.00-23.76News Coverage
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$69.29-6.8%$1.54 billionN/A-46.82News Coverage
Gap Down
Immunovant logo
IMVT
Immunovant
1.8$15.68-1.4%$1.54 billionN/A-12.16Unusual Options Activity
AlloVir logo
ALVR
AlloVir
1.4$23.21-5.2%$1.51 billionN/A0.00Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$33.44-4.6%$1.50 billionN/A0.00News Coverage
Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.17-0.0%$1.49 billion$35.23 million-14.18News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.66-3.2%$1.41 billionN/A0.00Insider Selling
High Trading Volume
News Coverage
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$30.07-1.9%$1.40 billionN/A-16.99
Alector logo
ALEC
Alector
1.3$17.37-13.0%$1.38 billion$21.22 million-7.79Insider Selling
Gap Down
Ocugen logo
OCGN
Ocugen
1.1$6.96-0.7%$1.31 billionN/A-4.70Gap Up
Translate Bio logo
TBIO
Translate Bio
1.6$17.26-2.1%$1.30 billion$7.80 million-16.13
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.77-3.1%$1.15 billionN/A-2.98Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.90-0.9%$1.15 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.51-0.6%$1.10 billion$32.16 million-9.67Analyst Upgrade
News Coverage
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02Gap Down
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.22-2.7%$1.04 billionN/A0.00
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.94-6.2%$1.03 billion$20.49 million-12.42Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.95-1.1%$1.02 billion$356.07 million6.84
Cortexyme logo
CRTX
Cortexyme
1.3$33.59-6.9%$992.65 millionN/A-14.00Gap Down
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.10-5.8%$922.43 million$42.74 million-223.33Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.63-0.9%$890.08 millionN/A-4.07
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.08-6.9%$887.99 million$250,000.00-7.15News Coverage
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.83-0.7%$883.45 million$69.89 million-4.49
Passage Bio logo
PASG
Passage Bio
1.8$16.34-4.4%$879.60 millionN/A0.00News Coverage
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.92-1.6%$852.18 million$22.99 million-10.60News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.02-2.8%$839.78 millionN/A-9.10News Coverage
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.